Servier challenges Mediator death figures
This article was originally published in Scrip
Executive Summary
The French company Servier has taken issue with the methodology used by researchers in a recent study to estimate the probable number of deaths and hospitalisations resulting from the use of its antidiabetic/anorectic drug Mediator (benfluorex), saying that the figures do not correspond to available pharmacovigilance data.